Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
What's The Controversy Behind Biogen's Alzheimer's Drug
12:39pm, Tuesday, 04'th Jan 2022
The U.S.'s approval of Biogen's Alzheimer's drug Aduhelm was heralded as a historic triumph in the fight against the memory-robbing disease. But so far, Biogen has reported only a fraction of Aduhelm
Why Biogen's Alzheimer's drug Aduhelm is so controversial
11:55am, Tuesday, 04'th Jan 2022
Biogen's Alzheimer's drug Aduhelm was heralded as a historic triumph against the memory-robbing disease. Now, the company is trying to keep it afloat.
Sage Therapeutics: Biogen''s Backing May See It Through
12:49am, Tuesday, 04'th Jan 2022 Seeking Alpha
Mondays Top Analyst Upgrades and Downgrades: Biogen, Cemex, Constellation Brands, Exxon Mobil, Fastly, Hilton Worldwide, McDonalds, Nike, PayPal, Peloton Interactive and More
01:47pm, Monday, 03'rd Jan 2022 24/7 Wall street
Biogen price target cut at Canaccord on pricing, labelling and efficacy concerns
12:59pm, Monday, 03'rd Jan 2022 Seeking AlphaMedicare Trying To Determine Coverage Of Biogen's Expensive Alzheimer's Drug: NYT
06:19am, Monday, 03'rd Jan 2022
Federal officials are struggling with a decision that could determine the future of Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug, Aduhelm, and whether significant numbers of patients use it. In Janu
Anti-Amyloid Drugs: The Failure Of Success
07:04am, Saturday, 01'st Jan 2022
Anti-Amyloid Drugs: The Failure Of Success
Biogen (BIIB) Surges Amid Rumors of Acquisition by Samsung
02:34pm, Thursday, 30'th Dec 2021
Biogen (BIIB) stock gains almost 10% on Dec 29 following speculations over its potential acquisition by the South-Korean conglomerate Samsung Group. However, both parties are yet to confirm.
Biogen tanks 8% after Samsung denies report it was in talks to buy the drugmaker
12:06pm, Thursday, 30'th Dec 2021
Samsung's biotech division disputed the report in a filing in South Korea, calling it "not true," according to a translated version.
Citi raises price targets for Ford, GM & Tesla, Biogen stock falls after Samsung rebuts acquisition
11:15am, Thursday, 30'th Dec 2021
Yahoo Finance Live's Brian Sozzi and Julie Hyman break down Citi's move to raise the price targets for key EV players Tesla, Ford, and GM, in addition to looking at the slumps Chinese tech companies a
Don't Panic About These 2 Stocks' Falling Prices on Thursday
09:28am, Thursday, 30'th Dec 2021
There are solid reasons why these companies don't appear to be participating in the market rally.
Why Biogen Shares Are Falling Today
09:20am, Thursday, 30'th Dec 2021
Biogen Inc (NASDAQ: BIIB) is trading lower Thursday morning after Samsung BioLogics denied that its parent company, Samsung Group, is looking to buy Biogen. Korea Economic Daily reported Wednesday tha
4 Biotechs That Could Be Potential Takeover Targets in 2022
08:26am, Thursday, 30'th Dec 2021
We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attrac
Biogen shares slump after Samsung Biologics denial of buyout report
05:01am, Thursday, 30'th Dec 2021
Biogen BIIB, +9.46% shares slumped 5% in early premarket action after Samsung Biologics 207940, +1.46% called a media report it was about to buy the U.S. company "not true." The brief statement didn't
Samsung in talks to buy Biogen for $42 bn: report
02:09am, Thursday, 30'th Dec 2021
Shares of Biogen surged Wednesday following a report that South Korean giant Samsung Group is in talks to acquire the US biotech company for more than $40 billion.
